Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major capsid protein L1 of Human papillomavirus type 6 is the primary structural protein forming the outer icosahedral shell of the HPV6 virus particle. L1 self-assembles into pentameric capsomers that interconnect via disulfide bonds to form a stable, 72-pentamer capsid of approximately 50 nm diameter, essential for encapsidating and protecting the viral genome. L1 is the immunodominant antigen in licensed HPV vaccines, as it elicits neutralizing antibodies that prevent viral entry into host cells. HPV6 is clinically significant as a leading cause of benign genital warts and recurrent respiratory papillomatosis, making the L1 protein a major target in prophylactic immunization strategies.
Induction of neutralizing antibodies blocking virus attachment or entry
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major capsid protein L1 (Human papillomavirus type 6) (L1).